News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Ben Westphalen: New biomarkers in non-colorectal dMMR tumors highlighted in NCI MATCH
Photo of Benedikt Westphalen taken from LinkedIn
Dec 16, 2024, 08:08

Ben Westphalen: New biomarkers in non-colorectal dMMR tumors highlighted in NCI MATCH

Ben Westphalen, Chair of Translational Research and Precision Medicine Working Group at ESMO, shared some insights from an article by Jonathan D. Schoenfeld et al. on X:

“In Clinical Cancer Research – new data from NCI MATCH:

Arm Z1D highlights new biomarkers in non-colorectal dMMR tumors: NGS-based MSI and immune infiltration predict response to PD-1 blockade with nivolumab.”

Next generation sequencing-based MSI scoring predict benefit in mismatch repair deficient tumors treated with nivolumab: follow-up on NCI-MATCH arm Z1D

Authors: Jonathan D. Schoenfeld, Nilofer S. Azad, Jacob Gross, Li Chen, Michael J. Overman, Katrina Kao, Latifa F. Jackson, Donna Brunnquell, Xiangning Bu, Christina Coppola, Ping Guan, Jennifer Lee, David Sims, Rebecca Fuchs, Jason L. Weirather, Kathleen L. Pfaff, Lauren Gunasti, Srin Ranasinghe, Stanley R. Hamilton, Victoria Wang, Peter J. O’Dwyer, Catherine J. Wu, Scott J. Rodig, David R. Patton, Lyndsay Harris

Ben Westphalen: New biomarkers in non-colorectal dMMR tumors highlighted in NCI MATCH

Ben Westphalen biomarkers Cancer research Catherine J. Wu CCR AACR Christina Coppola David R. Patton David Sims dMMR tumors Donna Brunnquell genetic data Immune Infiltration Jacob Gross Jason L. Weirather Jennifer Lee Jonathan D. Schoenfeld Kathleen L Pfaff Katrina Kao Latifa F. Jackson Lauren Gunasti Li Chen Lyndsay Harris Michael J. Overman NCI MATCH NGS-based MSI Nilofer S. Azad nivolumab non-colorectal tumors OncoDaily Oncology oncology research PD-1 blockade Peter J. O’Dwyer Ping Guan Precision Medicine Rebecca Fuchs Scott J Rodig Srin Ranasinghe Stanley R. Hamilton Victoria Wang Xiangning Bu
Special Coverage
Blog
Jan 15, 2025, 11:08
Why Dana-Farber Direct Connect? - Dana-Farber Cancer Institute
Blog
Jan 15, 2025, 10:56
Sachin H. Jain: The path forward for the US Health Insurance Industry begins with saying “We Are Sorry”
Blog
Jan 15, 2025, 08:23
Pashtoon Kasi: Different kind of liquid biopsies in guiding care of patients with cancer
Blog
Jan 15, 2025, 08:14
Chokri Ben Lamine: Immune Targets in Hematologic Malignancies
Blog
Jan 15, 2025, 08:06
Shushan Hovsepyan: 20 million participants at the first-ever 2025 CACA-OncoDaily-SPCC Cancer Summit
Opinion
Jan 15, 2025, 07:58
The Power of Equity: Funding Research to Close Gaps in Colorectal Cancer Outcomes
Blog
Jan 15, 2025, 07:53
Moses Echodu: Recounting 2024 and Looking at 2025 - Growth and Acceleration
Blog
Jan 15, 2025, 07:49
Breaking Ground in Genomics: India Launches "Genome India" Database - Canary Oncoceutics
Science
Jan 15, 2025, 07:40
Anirban Maitra: The impact of KRAS allelic status on outcomes in Pancreatic Cancer
Science
Jan 15, 2025, 07:31
Melvin LK Chua: Chromatin-related adaptation for acquired Radioresistance in Head and Neck Cancer
Blog
Jan 15, 2025, 07:27
Akhil Santhosh: I am among the recipients of the ASCO IDEA award 2025
Societies
Jan 15, 2025, 07:22
Benjamin Ebert: Excited to launch the Center for RAS Therapeutics